ZVRA (Zevra Therapeutics) 3-Year EBITDA Growth Rate : 3.40% (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics 3-Year EBITDA Growth Rate?

Zevra Therapeutics's EBITDA per Share for the three months ended in Sep. 2024 was $-0.61.

During the past 3 years, the average EBITDA Per Share Growth Rate was 3.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 54.00% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 34.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Zevra Therapeutics was 81.80% per year. The lowest was -12.70% per year. And the median was 14.70% per year.

Competitive Comparison of Zevra Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Zevra Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zevra Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's 3-Year EBITDA Growth Rate falls into.

Zevra Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Zevra Therapeutics (NAS:ZVRA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Zevra Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Zevra Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (NAS:ZVRA) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

1GDA:Germany

Address

1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747

Website

https://www.zevra.com

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Executives

Watton Corey Michael	director	22045 KAREN STREET, ELKHORN NE 68022
R. Laduane Clifton	officer: VP Fin & Corp Controller	C/O KEMPHARM, INC., 1170 CELEBRATION BLVD., #103, CELEBRATION FL 34747
Thomas Anderson	director	215 FIRST STREET, CAMBRIDGE MA 02142
John B Bode	director	C/O TRIBUNE PUBLISHING COMPANY, 202 W. FIRST STREET, LOS ANGELES CA 90012
Neil F. Mcfarlane	director, officer: President and CEO	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Joshua Schafer	officer: CCO & EVP, Bus. Development	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Douglas W Calder	director	324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Wendy L Dixon	director
Tamara A Seymour	director	C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Timothy J. Sangiovanni	officer: VP, Corporate Controller	C/O KEMPHARM, INC., 2500 CROSSPARK RD, STE E-126, CORALVILLE IA 52241
Matthew R Plooster	director	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
David S Tierney	director	C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Richard W Pascoe	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Christopher Posner	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Travis C Mickle	director, 10 percent owner, officer: President & CEO	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241